Abstract
Function of astroglia in the modulation of availability, release and clearance (inactivation) of Glu and GABA within the central nervous system is reviewed. Net synthesis of Glu through Gln synthethase exclusively localized in astrocytes can only occur by a metabolic coupling between neurons and astrocytes. Two (GLAST and GLT-1) of the five Glu transporters cloned preferentially expressed in astrocytes perform the astroglial Glu uptake of very high capacity. Moreover, astrocytes have been shown to mediate Glu release by a mechanism mimicking vesicular release. Biosynthesis of GABA in neurons is brought about by decarboxylation of Glu catalyzed by a pyridoxal phosphate requiring enzyme (GAD) that exists in two isoforms (GAD65 and GAD67) exhibiting different subcellular localization and regulatory properties. Detailed studies of GABA synthesis in GABAergic neurons using 13C NMR spectroscopy have provided evidence for direct involvement of the tricarboxylic acid cycle. Synaptically released GABA taken up into surrounding astrocytes is converted to either CO2 or Gln. Two reports on the release of GABA in rat dorsal root ganglia indicated that glial cells may perform GABA release as well. Gln formed from GABA in astrocytes can be transferred to GABAergic neurons and subsequently converted to GABA. Inhibition of either degradation or clearance of GABA has been successfully applied in the development of antiepileptics such as vigabatrin or tiagabine. So far, no specific strategy has been developed aimed at stimulating Glu transport.
Keywords: Metabolic coupling between neurons and astrocytes, GABA-Glu-Gln cycle, GLAST, GLT-1, tiagabine, BGT- 1/GAT2 inhibitor EF 1502
Current Topics in Medicinal Chemistry
Title: Glial Modulation of GABAergic and Glutamat ergic Neurotransmission
Volume: 6 Issue: 10
Author(s): Arne Schousboe and Helle S. Waagepetersen
Affiliation:
Keywords: Metabolic coupling between neurons and astrocytes, GABA-Glu-Gln cycle, GLAST, GLT-1, tiagabine, BGT- 1/GAT2 inhibitor EF 1502
Abstract: Function of astroglia in the modulation of availability, release and clearance (inactivation) of Glu and GABA within the central nervous system is reviewed. Net synthesis of Glu through Gln synthethase exclusively localized in astrocytes can only occur by a metabolic coupling between neurons and astrocytes. Two (GLAST and GLT-1) of the five Glu transporters cloned preferentially expressed in astrocytes perform the astroglial Glu uptake of very high capacity. Moreover, astrocytes have been shown to mediate Glu release by a mechanism mimicking vesicular release. Biosynthesis of GABA in neurons is brought about by decarboxylation of Glu catalyzed by a pyridoxal phosphate requiring enzyme (GAD) that exists in two isoforms (GAD65 and GAD67) exhibiting different subcellular localization and regulatory properties. Detailed studies of GABA synthesis in GABAergic neurons using 13C NMR spectroscopy have provided evidence for direct involvement of the tricarboxylic acid cycle. Synaptically released GABA taken up into surrounding astrocytes is converted to either CO2 or Gln. Two reports on the release of GABA in rat dorsal root ganglia indicated that glial cells may perform GABA release as well. Gln formed from GABA in astrocytes can be transferred to GABAergic neurons and subsequently converted to GABA. Inhibition of either degradation or clearance of GABA has been successfully applied in the development of antiepileptics such as vigabatrin or tiagabine. So far, no specific strategy has been developed aimed at stimulating Glu transport.
Export Options
About this article
Cite this article as:
Schousboe Arne and Waagepetersen S. Helle, Glial Modulation of GABAergic and Glutamat ergic Neurotransmission, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323719
DOI https://dx.doi.org/10.2174/156802606777323719 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Changes in Rat Plasma After Epilepsy by UPLC-MS/MS
Current Pharmaceutical Analysis Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets α7-Nicotinic Receptors and Cognition
Current Drug Targets Voltage-Gated Sodium Channel Blockers; Target Validation and Therapeutic Potential
Current Topics in Medicinal Chemistry Diagnostic Biomarkers of Epilepsy
Current Pharmaceutical Biotechnology Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Selective Modulators of α<sub>5</sub>-Containing GABA<sub>A</sub> Receptors and their Therapeutic Significance
Current Drug Targets Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Inhibition of Bacterial Carbonic Anhydrases as a Novel Approach to Escape Drug Resistance
Current Topics in Medicinal Chemistry Teratogenic Potential of Atypical Antipsychotic Drugs, Quetiapine and Aripiprazole in Rats
Current Psychopharmacology Opioid Receptor Ligands Derived from Food Proteins
Current Pharmaceutical Design AAV as An Immunogen
Current Gene Therapy Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry